UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data

UniQure NV shares declined after the FDA deemed the clinical data for its experimental gene-therapy for Huntington's disease as insufficient, leading to a potential delay in the drug's approval.